araag2/HINT huggingface dataset:
Clinical trial NCT00624052 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: fixed-dose combination of telmisartan 40mg+amlodipine 10mg, fixed-dose combination of telmisartan 80mg+amlodipine10mg
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

        - diagnosis of essential hypertension

        Exclusion Criteria:

          -  pregnancy, breast-feeding, unwilling to use effective contraception (if female of
             child-bearing potential).

          -  development of any condition in the preceding trial that could be worsened by
             telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg
             (T80/A10).

          -  discontinuation from the preceding trial.

          -  known or suspected secondary hypertension.

          -  mean seated systolic blood pressure (SBP) >= 180 mmHg and/or mean seated diastolic
             blood pressure (DBP) >= 120 mmHg at any visit.

          -  any clinically significant hepatic impairment or severe renal impairment bilateral
             renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal
             transplant.

          -  clinically relevant hyperkalaemia.

          -  uncorrected volume or sodium depletion.

          -  primary aldosteronism.

          -  hereditary fructose or lactose intolerance.

          -  symptomatic congestive heart failure.

          -  patients who have previously experienced symptoms characteristic of angioedema during
             treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor
             blockers (ARBs).

          -  any new drug or alcohol dependency since signing consent of the preceding trial.

          -  concurrent participation in another clinical trial or any investigational therapy
             since completing the preceding trial.

          -  hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the
             aortic or mitral valve.

          -  known allergic hypersensitivity to any component of the formulations under
             investigation. [Includes known hypersensitivity to telmisartan or other ARBs or
             amlodipine or other dihydropyridine calcium channel blockers (CCBs).] non-compliance
             with study medication (defined as <80% or >120%) during the preceding trial.

          -  administration of ARBs or dihydropyridine CCBs (apart from trial medication). any
             other clinical condition which, in the opinion of the investigator, would not allow
             safe completion of the protocol and safe administration of telmisartan and amlodipine.
Clinical trial NCT00365859 (phase 3, status: completed)
Conditions: autistic disorder, behavioral symptoms
ICD codes: F84.0
Drugs: aripiprazole
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria - Rollover:

          -  Completed 8 weeks of treatment in one of the following double-blind clinical trials:
             CN138-178 [NCT00332241] or CN138-179 [NCT00337571]

          -  No significant protocol violations and sufficient medical justification to continue on
             open-label treatment with aripiprazole

        Inclusion Criteria - De Novo:

          -  Meets current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
             Text Revision (DSM-IV TR) diagnostic criteria for AD and demonstrates serious
             behavioral problems - diagnosis confirmed by Autism Diagnostic Interview-Revised
             (ADI-R) or the patient meets the current Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition, Text Revision (DSM-IV TR) diagnostic criteria for AD and
             has a history of behavioral problems that are currently being treated with
             psychotropic medication

          -  Mental age of at least 18 months

          -  Male or female 6 to 17 years of age, inclusive, at the time of enrollment

        Exclusion Criteria:

          -  Patients considered treatment resistant to neuroleptic medication based on lack of
             therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks
             each

          -  Patients previously treated and not responding to aripiprazole treatment

          -  The patient is currently diagnosed with another disorder on the autism spectrum,
             including pervasive developmental disorder-not otherwise specified (PDD-NOS),
             Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or Childhood Disintegrative
             Disorder

          -  Current diagnosis of bipolar disorder, psychosis, schizophrenia, or major depression

          -  A seizure in the past year

          -  History of severe head trauma or stroke

          -  Non-pharmacologic therapy (e.g. psychotherapy, behavior modification) should be stable
             prior to screening and consistent throughout the study
Clinical trial NCT00134563 (phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: teriflunomide, placebo (for teriflunomide)
SMILES: C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Multiple sclerosis [MS] subject who was ambulatory (EDSS of ≤ 5.5)

          -  Exhibiting a relapsing clinical course, with or without progression (relapsing
             remitting, secondary progressive or progressive relapsing);

          -  Meeting McDonald's criteria for MS diagnosis;

          -  Experienced at least 1 relapse over the 1 year preceding the trial or at least 2
             relapses over the 2 years preceding the trial;

          -  No relapse onset in the preceding 60 days prior to randomization;

          -  Clinically stable during the 30 days prior to randomization, without
             adrenocorticotrophic hormone [ACTH] or systemic steroid treatment.

        Exclusion Criteria:

          -  Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major
             systemic disease;

          -  Significantly impaired bone marrow function;

          -  Pregnant or nursing woman;

          -  Alcohol or drug abuse;

          -  Use of cladribine, mitoxantrone, or other immunosuppressant agents such as
             azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before
             enrollment;

          -  Any known condition or circumstance that would prevent in the investigator's opinion
             compliance or completion of the study;
Clinical trial NCT00234377 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: seroquel sr
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who in their own and/or in the Investigator's opinion, consider ongoing
             antipsychotic treatment inadequate, because of insufficient efficacy and/or
             tolerability.

          -  Female patients of childbearing potential must have a negative serum pregnancy test at
             enrolment and be willing to use a reliable method of birth control, ie, barrier
             method, oral contraceptive, implant, dermal contraception, long-term injectable
             contraceptive, intrauterine device, or tubal ligation during the study.

          -  Able to understand and comply with the requirements of the study, as judged by the
             Investigator.

        Exclusion Criteria:

          -  Meeting the criteria for any other (than schizophrenia) Diagnostic and Statistical
             Manual of Mental Disorders, 4th Edition (DSM-IV) Axis I diagnosis, concomitant organic
             mental disorder or mental retardation.

          -  Substance abuse or dependence as defined by DSM-IV and not in full remission. A urine
             drug screen test will be performed. The Investigator will evaluate the results along
             with medical history to determine if the patient meets DSM-IV criteria for substance
             abuse or dependence.

          -  Risk of transmitting human immunodeficiency virus (HIV) or hepatitis B, via blood or
             other body fluids, as judged by the Investigator.

          -  Patients who, in the opinion of the Investigator, pose an imminent risk of suicide or
             a danger to self or others.
Clinical trial NCT01135992 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

          -  HbA1c maximum 10 % by central laboratory analysis

          -  Current treatment with basal-oral therapy (BOT) (no prandial insulin ever) consisting
             of: at least three months with insulin glargine once daily (average prescribed dose
             must have been unchanged (within plus/minus 10%) for four weeks prior to Visit 1 as
             confirmed by patient records or verbal confirmation by the subject) in combination
             with stable (unchanged doses for at least 3 months prior to Visit 1) OAD (metformin,
             insulin secretagogues, pioglitazone, sitagliptin or alpha-glucosidase-inhibitor)
             treatment in any approved (according to label) dose or combination

        Exclusion Criteria:

          -  Use within the last three months prior to Visit 1 of: Exenatide, Liraglutide or
             Thiazoledinediones (TZDs) other than Pioglitazone

          -  Cardiovascular disease (CVD) defined as: stroke; decompensated heart failure New York
             Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina
             pectoris; or coronary arterial bypass graft or angioplasty within the last six months
             prior to Visit 1

          -  Recurrent severe hypoglycaemia (more than one severe hypoglycaemic episode during the
             last 12 months), or hypoglycaemic unawareness as judged by the Investigator, or
             hospitalisation for diabetic ketoacidosis during the previous six months

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements

          -  Previous participation in this trial. Participation is defined as started on trial
             medication. Rescreening of screening failures is allowed only once within the limits
             of the recruitment period

          -  Known or suspected hypersensitivity to trial products or related products
Clinical trial NCT00199368 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: istradefylline ( kw-6002)
SMILES: [H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC
Eligibility criteria:

        Inclusion Criteria:

          -  Completion of study 6002-EU-007, 6002-US-013 or 6002-US-018

          -  Non-pregnant and either not of childbearing potential or using specified contraception

        Exclusion Criteria:

          -  History of psychotic illness

          -  Variant/atypical Parkinson's disease

          -  Cancer within 5 years of enrollment

          -  ALT/AST levels > 1.5 times ULN

          -  Seizure disorder

          -  Neuroleptic malignant syndrome
Clinical trial NCT00321984 (phase 3, status: completed)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: dexlansoprazole mr, dexlansoprazole mr, placebo
SMILES: CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects identifying their main symptom as a burning feeling in the mid epigastric
             area and/or chest area (ie, heartburn).

          -  Subject has a history of episodes of heartburn for 6 months or longer prior to
             Screening.

          -  Subject must have a history of episodes of heartburn for 4 or more days during the 7
             days prior to Day -1.

        Exclusion Criteria:

          -  Endoscopic Barrett's esophagus and/or definite dysplastic changes. History of
             dilatation of esophageal strictures.

          -  Subjects with erosive esophagitis (EE) as shown by endoscopy.

          -  Evidence of uncontrolled systemic disease. Co-existing diseases affecting the
             esophagus. Current or history of Zollinger-Ellison syndrome.

          -  Subject has abnormal laboratory values.

          -  Subjects with active gastric or duodenal ulcers within 4 weeks of the first dose.

          -  Subject known to have acquired immunodeficiency syndrome (AIDS).

          -  Known hypersensitivity to any proton pump inhibitor (PPI), any component of
             Dexlansoprazole MR, or antacid.

          -  Use of prescription or non-prescription PPIs, histamine (H2) receptor antagonists, or
             sucralfate.

          -  Chronic (>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or
             cyclo-oxygenase-2 (COX-2) inhibitors.

          -  Use of antacids (except for study-supplied Gelusil® ).

          -  Use of drugs with significant anticholinergic effects.

          -  Subjects who cannot discontinue the use of misoprostol or prokinetics

          -  Need for continuous anticoagulant therapy.

          -  Females who are pregnant or lactating.

          -  History of gastrointestinal surgery except for simple oversew of ulcer.

          -  History of cancer within 3 years prior to screening.

          -  Subject has participated in a previous Dexlansoprazole study.

          -  Subjects who, in the opinion of the investigator, are unable to comply with the
             requirements of the study or are unsuitable for any reason.
Clinical trial NCT01135433 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ipragliflozin, placebo, metformin
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetic patients receiving with metformin mono-therapy for at least 6 weeks

          -  HbA1c value between 7.0 and 9.5%

          -  Body Mass Index (BMI) 20.0 - 45.0 kg/m2

        Exclusion Criteria:

          -  Type 1 diabetes mellitus patients

          -  Serum creatinine > upper limit of normal

          -  Estimated GFR < 60ml/min/1.73m2

          -  Proteinuria (albumin/creatinine ratio > 300mg/g)

          -  Dysuria and/or urinary tract infection, genital infection

          -  Significant renal, hepatic or cardiovascular diseases

          -  Severe gastrointestinal diseases
Clinical trial NCT00105443 (phase 3, status: completed)
Conditions: carcinoma, hepatocellular
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib (nexavar, bay43-9006), placebo
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ages eligible for study: 18 years and above, Genders eligible for study: both

          -  Patients who have a life expectancy of at least 12 weeks

          -  Patients with histologically or cytologically documented Hepatocellular Carcinoma
             (HCC)

          -  Patients must have at least one tumor lesion that meets both of the following
             criteria: (1) Accurately measured in at least one dimension according to RECIST
             (Response Evaluation Criteria in Solid Tumors) (2) Not previously treated with local
             therapy

          -  Patients who have an ECOG (Eastern Cooperative Oncology Group) PS (Performance Status)
             of 0, 1, or 2

        Exclusion Criteria:

          -  Previous or concurrent cancer that is distinct in primary site or histology from HCC,
             EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder
             tumors (Ta [Noninvasive papillary carcinoma], Tis [Carcinoma in situ: "flat tumor"] &
             T1 [Tumor invades subepithelial connective tissue]). Any cancer curatively treated > 3
             years prior to entry is permitted

          -  Renal failure requiring hemo- or peritoneal dialysis

          -  History of cardiac disease

          -  Active clinically serious infections

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Known central nervous system tumors including metastatic brain disease

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry
Clinical trial NCT00226668 (phase 3, status: withdrawn)
Conditions: brain edema, brain tumor
ICD codes: C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, D49.6
Drugs: hcrf, placebo hcrf
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    alternate study projected to assess imaging endpoints versus clinical endpoints.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of a primary malignant glioma.

          -  Symptomatic peritumoral brain edema requiring initiation or increase of dexamethasone
             treatment.

          -  If a patient is on dexamethasone for treatment of symptomatic peritumoral brain edema,
             the dose must be stable and should not exceed 24mg/dl for a minimum of 7 days prior to
             Baseline.

          -  Presence of peritumoral brain edema confirmed by MRI scan or comparable diagnostic
             technology obtained within 21 days of Baseline.

          -  Capable of self-administration of subcutaneous injections twice daily for 8 weeks or
             availability of assistance from caregiver.

        Exclusion Criteria:

          -  Need for surgery, radiosurgery or radiation therapy or the introduction of new
             chemotherapeutic regime within 2 weeks of study treatment.

          -  Systemic steroid use for any other indication than peritumoral brain edema.

          -  Patients on dexamethasone or anticonvulsant therapy.

          -  Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine
             metabolic disease which could put the patient at unusual risk for study participation.

          -  Central nervous system (CNS) infection.

          -  Conditions that are considered contradictions for patients to receive niacin
Clinical trial NCT01250379 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bevacizumab [avastin], chemotherapy
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients, >/= 18 years of age

          -  Histologically confirmed HER2-negative breast cancer

          -  Disease progression during or following first-line treatment with Avastin and
             chemotherapy for locally recurrent or metastatic breast cancer

          -  Avastin treatment in first-line setting must have been a minimum of 4 cycles (15
             mg/kg) or 6 cycles (10 mg/kg) in combination with chemotherapy

          -  ECOG performance status 0-2

          -  At least 28 days since prior radiation therapy or surgery and recovery from treatment

        Exclusion Criteria:

          -  Anti-angiogenic therapy or anti-vascular endothelial growth factors other than Avastin
             for first-line treatment

          -  Active malignancy other than superficial basal cell and superficial squamous cell
             carcinoma of the skin, or in situ carcinoma of the cervix or breast within the last 5
             years

          -  Inadequate renal function

          -  Clinically relevant cardio-vascular disease

          -  Known CNS disease except for treated brain metastases

          -  Chronic daily treatment with high-dose aspirin (>325 mg/day) or clopidogrel (>75
             mg/day)

          -  Pregnant or lactating women
Clinical trial NCT00400088 (phase 3, status: terminated)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: paroxetine, lithium
SMILES: FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1, [Li+]
Reason stopped: 
    recruitment difficulties
  
Eligibility criteria:

        Inclusion Criteria:

          -  Not currently participating in a drug or medical device clinical trial

          -  Male or female over the age of 18

          -  DSM - IV Diagnosis of major depression

          -  Positive family history of bipolar disorder or completed suicide

        Exclusion Criteria:

          -  Not able to give informed consent

          -  Pregnant or breast-feeding

          -  Current additional psychiatric diagnoses including Panic Disorder, Post -Traumatic
             Stress Disorder (PTSD) or Psychosis

          -  History of mania or hypomania

          -  Active substance abuse or dependence in the last 6 months

          -  Current depressive episode less than 4 weeks or greater than 12 months in duration

          -  Current or prior adequate trial of lithium or paroxetine

          -  Current use of other medications such as antidepressants for the treatment of
             depression

          -  Clinically significant medical illness, in particular kidney problems
Clinical trial NCT00687804 (phase 3, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: ranibizumab, sham to ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Visual acuity impairment

          -  Diabetic macular edema in at least one eye

          -  Type 1 or type 2 diabetes mellitus

          -  Medication for the diabetes treatment must be stable for the last 3 months

        Exclusion Criteria:

          -  Patients with uncontrolled systemic or ocular diseases

          -  Laser photocoagulation in the study eye for the last 3 months

          -  Any history of any intraocular surgery in the study eye within the past 3 months

          -  Blood pressure > 160/100 mmHg

        Extension Inclusion Criteria:

        -Completion of the Core Study
Clinical trial NCT00116181 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: etanercept
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Gender: Male and Female

          -  Minimum Age: 18

          -  Maximum Age: 70

        Exclusion Criteria:

          -  Healthy Volunteers